Table 3.

Unadjusted and adjusted progression free and overall survival in patients treated with bevacizumab vs. standard treatment, stratified by TCGA molecular subtype

	Progression Free Survival				Overall Survival
	Unadjusted		Adjusted		Unadjusted		Adjusted
	HR (95% CI)	p- value	HR (95% CI)	p-value	HR (95% CI)	p- value	HR (95% CI)	p-value
All (n=359)	0.68 (0.53–0.89)	0.005	0.64 (0.49–0.83)	0.0.0008	0.68 (0.45–1.03)	0.07	0.66 (0.44–1.00)	0.05
Mesenchymal (n=68)	0.78 (0.44–1.40)	0.41	0.80 (0.45–1.43)	0.45	0.56 (0.23–1.34)	0.19	0.55 (0.23–1.32)	0.18
Proliferative (n=96)	0.55 (0.34–0.90)	0.016	0.45 (0.27–0.74)	0.0015*	0.52 (0.25–1.08)	0.08	0.50 (0.24–1.03)	0.06
Immunoreactive (n=122)	0.67 (0.42–1.05)	0.08	0.66 (0.42–1.05)	0.08	0.76 (0.33–1.76)	0.52	0.72 (0.31–1.67)	0.45
Differentiated (n=73)	0.85 (0.46–1.58)	0.61	0.75 (0.40–1.39)	0.36	1.41 (0.53–3.71)	0.49	1.55 (0.59–4.10)	0.38

^*P value for subgroup comparison significant after Bonferroni correction. Adjusted analyses included high risk of progression (suboptimal stage III, inoperable Stage III, and all stage IV patients), age, grade, and histology.